[ad_1]
Swissmedic today approved the Covid vaccine from manufacturer Johnson & Johnson. The pharmaceutical authority has given the green light to the third vaccine against the crown. Unlike the previously approved vaccines from Biontech / Pfizer and Moderna, the Johnson & Johnson advantage is that you only need one scoop.
Therefore, the vaccine could be a game changer in vaccination strategy. But the vaccine from Janssen-Cilag, a Johnson & Johnson subsidiary, is not among the nearly 36 million doses of vaccines that Switzerland has obtained.
BAG deliberately refrains from using Swiss-made vaccines
Because the Federal Office of Public Health (BAG) does without it. The deputy director of BAG, Nora Kronig (40), justified it with the fact that the delivery would be too late and would only be possible from the third quarter. Additionally, FOPH currently relies on mRNA vaccines, which are more effective, especially for vulnerable people. They can also be adjusted quickly.
Johnson & Johnson’s technology, on the other hand, is based on a human adenovirus-based vector vaccine. The study data presented shows an average effectiveness of 66.9 percent in the age groups examined, as Swissmedic writes.
The vaccine was designed in the Bern laboratory by Janssen Vaccines, a subsidiary of the US pharmaceutical giant Johnson & Johnson. Bümpliz virus hunters developed an Ebola vaccine in 2015, and now its latest preparation is supposed to help defeat Covid-19.
AstraZeneca should be number 4
The British-Swedish AstraZeneca uses the same technology. The federal government has ordered 5.3 million doses of this vaccine. The approval is still under review because Swissmedic was still waiting for the study data. Since these were also released on Monday in the US, AstraZeneca should also be approved in the near future. (gnc)
Posted: 03/22/2021, 39 minutes ago
Last updated: 22.03.2021, 1 minute ago
